Cosmo Bio Co 3386.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 3386.T. It has been listed since 27 September 2005. In the fiscal year to 31 December 2025, it reported revenue of ¥10.77bn and net income of ¥336.0m. At that date it held total assets of ¥12.66bn and shareholders' equity of ¥9.37bn.

Cosmo Bio Co., Ltd. engages in export, import, and sale of bio-research reagents, instruments and software, and clinical diagnostics. The company is headquartered in Koto-Ku, Tokyo-To. The company went IPO on 2005-09-27. Research reagents business imports majority research reagents from United States and Europe, which are prioritized in life science related research. In the equipment business, the Company handles equipment specialized in life science research, purchases goods from a wide range of domestic and overseas, and mainly sells it to the domestic market. The equipment includes ultrasonic cell disruption equipment, bioimaging related equipment and research consumables. The firm provides clinical test drugs mainly used at hospitals and testing centers.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Norihiko ShibayamaPresident, Representative Director, since 2017
• Mr. Masanori HayashiDirector of Finance, Director, since 2023
• Ms. Junko TochigiManaging Director, Director of Planning, President of Subsidiary, since 2017
• Mr. Ken HasegawaExecutive Officer
• Mr. Junichiro HaraguchiIndependent Director
• Mr. Haruo SasakiIndependent Director
• Mr. Kazutoshi SatoIndependent Director
• Mr. Kazuya ShimamuraIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.